PMV Pharmaceuticals, Inc.
corporate_fare Company Profile
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for PMVP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PMVP spans 8-K, 10-Q, 424B5, DEF 14A.
Recent high-impact activity:
- Rezatapopt Posts 48% ORR in Pivotal Ovarian Analysis; PMV Pharma Targets Q1 2027 NDA
- Rezatapopt Hits 48% Response Rate in Platinum-Resistant Ovarian Cancer; NDA Set for Q1 2027
- PMV Pharma's Q3 10-Q Clears Going Concern Warning, Cash Runway Now Into Q1 2028
- PMV Pharma Posts $34.4M Q3 Loss as Cash Runway Tightens
- PMV Pharma Finalizes $50.8M Offering with FDA-Linked Warrant Reset Terms
Financial Snapshot
Short Interest & Short Volume
5.62 days to coverFINRA reported short interest of 2,153,550 shares in PMVP as of the October 30, 2026 settlement, a 5.8% decrease from the prior period — about 5.6 days to cover at its recent average daily volume. On November 20, 2026, 56.7% of PMVP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for PMVP, detected from its recent SEC filings · based on capital-structure filings through 2026-09-01.
Underwritten Offering with Warrants · NDA-Triggered Warrant Reset
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →